Skip to content
Brand AI

Enliven Therapeutics, Inc.

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2026

    Enliven Therapeutics appoints Kristine Ball to Board of Directors

    Enliven Therapeutics, Inc. (Nasdaq: ELVN) announced on October 14, 2026 the appointment of biopharmaceutical executive Kristine Ball to its Board of Directors, effective immediately, as the company prepares to initiate the pivotal Phase 3 trial of relcobatinib before year-end 2026 and plans for commercialization.

    Source